First Clinical Guidelines for Cardiovascular–Kidney–Metabolic (CKM) Syndrome: JAMA | July 2026

Introduction:

Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the interconnected relationship between obesity, type 2 diabetes, chronic kidney disease (CKD), and cardiovascular disease (CVD). These first multidisciplinary guidelines from the AHA, ACC, ADA, and American Society of Nephrology provide a unified framework for screening, staging, risk assessment, and management.

Key Recommendations:

• Obesity is the upstream driver of CKM syndrome. Weight management should be considered a primary therapeutic target rather than a cosmetic concern.
• Assess both BMI and waist circumference annually, as abdominal obesity is a stronger predictor of cardiometabolic risk than BMI alone.
• Lifestyle modification remains first-line therapy, but anti-obesity medications (particularly GLP-1 receptor agonists) and metabolic surgery should be considered when appropriate.
• Routine CKD screening using eGFR and urine albumin-to-creatinine ratio (UACR) is recommended, with albuminuria regarded as a modifiable therapeutic target.
• Screen for associated conditions, including MASLD, pre-heart failure, obstructive sleep apnea, hypertension, diabetes, and dyslipidemia.
• Use the PREVENT risk calculator instead of older cardiovascular risk equations to estimate 10-year and 30-year cardiovascular risk and guide treatment decisions.
• GLP-1 receptor agonists, SGLT2 inhibitors, and non-steroidal mineralocorticoid receptor antagonists are emphasized because they provide benefits across multiple CKM domains.
• The guidelines introduce a 5-stage CKM classification (Stages 0–4), allowing earlier intervention before the development of overt cardiovascular disease.
• Team-based multidisciplinary care involving primary care physicians, cardiologists, nephrologists, endocrinologists, obesity specialists, nurses, pharmacists, and diabetes educators is strongly recommended.
• Social determinants of health should be routinely assessed, recognizing their major influence on CKM outcomes and access to care.

Clinical Impact:

These landmark guidelines shift healthcare from treating individual diseases to managing CKM syndrome as a single interconnected disorder. Early identification of obesity, CKD, diabetes, and cardiovascular risk allows preventive intervention before irreversible organ damage develops.

Bottom Line:

CKM syndrome establishes a new integrated model of chronic disease management. By recognizing obesity as the root cause and emphasizing early screening, comprehensive risk assessment, multidisciplinary care, and therapies with multisystem benefits, these guidelines redefine preventive cardiometabolic medicine.